Blue Cross Blue Shield Denied Your Chemotherapy? How to Appeal
Blue Cross Blue Shield denied coverage for chemotherapy and cancer treatment? Learn why Blue Cross Blue Shield denies these claims, what laws protect you, and how to write a winning appeal.
Blue Cross Blue Shield serves 115 million members across its 33 independent licensee plans. Despite this broad coverage, chemotherapy claims are frequently denied — and chemotherapy denials are among the most urgent because delay in cancer treatment directly affects outcomes. Under the ACA, you have the right to an expedited appeal within 72 hours if delay would seriously jeopardise your health. This is a legal right, not a discretionary option, and it applies to active chemotherapy denials.
Why Insurers Deny BCBS Chemotherapy Claims
Not medically necessary. BCBS's utilisation review team may determine the specific chemotherapy regimen does not meet its internal clinical criteria. This is particularly common for newer targeted therapies, immunotherapy agents (checkpoint inhibitors), and antibody-drug conjugates where BCBS's internal policies have not yet caught up with NCCN Clinical Practice Guidelines in Oncology or ASCO clinical practice guidelines.
Experimental or investigational. BCBS may classify a chemotherapy agent or regimen as experimental even where it is supported by NCCN Category 1 or 2A evidence, FDA approval, or ASCO guidelines. More than 40 states require coverage of off-label chemotherapy uses supported by recognised compendia — the NCCN Drugs and Biologics Compendium is the most authoritative reference, and state off-label cancer coverage laws require coverage of treatments listed there for fully insured plans.
Prior authorisation not obtained. BCBS requires pre-authorisation for virtually all chemotherapy regimens and oncology drug administration. Claims submitted without prior authorisation are denied regardless of clinical merit.
Off-label regimen not supported. BCBS may deny chemotherapy used in a combination, sequence, or at a dosing schedule not specifically listed in its oncology drug policies — even where the regimen is consistent with published clinical trial data and NCCN recommendations. California (Health and Safety Code 1367.21) and New York (Insurance Law 3216(i)(22)) have among the strongest off-label cancer drug coverage laws in the country.
Insufficient documentation of cancer diagnosis and staging. BCBS may deny because the clinical records do not establish the specific cancer type, stage, histology, or molecular biomarker profile (e.g., KRAS mutation status, HER2 amplification, MSI-H/dMMR status) required to justify the chemotherapy regimen under BCBS's policy.
Step therapy requirement not met. BCBS may require trial of a first-line chemotherapy regimen before approving a second-line or combination therapy, even where your oncologist has recommended beginning with a more aggressive regimen based on specific clinical factors.
How to Appeal a BCBS Chemotherapy Denial
Step 1: Request Expedited Review If Clinically Urgent
Under the ACA, if delay in chemotherapy treatment would seriously jeopardise your health, request an expedited internal appeal. BCBS must respond within 72 hours. Your oncologist should submit a letter certifying that expedited review is medically necessary. Do not wait for the standard appeal timeline when active cancer treatment is being denied.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Step 2: Obtain the Denial Letter and BCBS Oncology Policy
Request the written denial letter and the specific Clinical Policy Bulletin or Medical Policy BCBS applied to your chemotherapy claim. Also request under ACA rights all documents BCBS used in making the denial decision, including any clinical reviewer's notes. Identify your specific BCBS licensee — Anthem BCBS, Blue Shield of California, BCBS of Michigan, and Highmark BCBS each maintain their own oncology policies.
Step 3: Have Your Oncologist Request Peer-to-Peer Review
A direct clinical conversation between your oncologist and BCBS's oncology medical reviewer is the most effective single intervention for chemotherapy medical necessity denials. The oncologist should address the specific denial criteria on the call, cite the NCCN evidence category for the prescribed regimen, and present the patient's specific molecular profile, staging, and prior treatment history.
Step 4: Build the NCCN and ASCO Evidence Package
Pull the NCCN Drugs and Biologics Compendium entry for your chemotherapy drug(s) and cancer indication. Print the relevant NCCN Clinical Practice Guideline algorithm pages showing the specific regimen as a recommended option for your cancer type and stage. Identify the applicable ASCO guideline recommendation. For newly approved agents or combinations, include the key clinical trial publications (phase III trial data) and FDA approval information that formed the basis for NCCN inclusion.
Step 5: File the Internal Appeal Within 180 Days
Under the ACA, you are entitled to at least one level of internal appeal. Include your complete evidence package: oncologist letter, NCCN Compendium entry, NCCN Clinical Practice Guideline pages, ASCO guideline citation, key clinical trial publications, and state off-label coverage law citation if applicable. Cite specific NCCN evidence categories — Category 1 (based on high-level evidence with uniform NCCN consensus) carries the most weight with reviewers.
Step 6: Request External Independent Review and File a State Complaint
If the internal appeal is denied, immediately request external review by an IRO with oncology expertise. External oncology reviewers given NCCN documentation overturn chemotherapy denials at high rates, particularly for treatments with strong NCCN evidence. Simultaneously file a state insurance department complaint citing the clinical evidence and state off-label coverage law if applicable. Note that state laws apply to fully insured plans — self-funded ERISA plans are subject to federal external review rights instead.
What to Include in Your Appeal
- BCBS's written denial letter with the specific Medical Policy or Clinical Policy Bulletin applied
- NCCN Drugs and Biologics Compendium entry for your chemotherapy regimen and cancer indication
- NCCN Clinical Practice Guideline algorithm pages showing the regimen as recommended for your cancer type, stage, and biomarker profile
- ASCO Clinical Practice Guideline citation for the relevant recommendation
- Oncologist's letter: diagnosis and staging, molecular biomarker profile, specific regimen prescribed, NCCN/ASCO support, clinical consequences of denial
- State off-label cancer coverage law citation (for fully insured plans in applicable states)
Fight Back With ClaimBack
BCBS chemotherapy denials involving NCCN-supported regimens are among the most legally and clinically vulnerable denial categories — the combination of strong NCCN evidence, ASCO guideline support, and state off-label coverage laws creates a powerful legal framework for appeal. The urgency of cancer treatment also means that expedited appeal rights and the 72-hour review standard are real tools, not theoretical ones. ClaimBack generates a professional appeal letter in 3 minutes.
Start your free claim analysis →
Free analysis · No credit card required · Takes 3 minutes
Related Reading
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides